Email to a Colleague
Medscape Conference Coverage, based on selected sessions at the:
European Society of Cardiology Congress 2004
August 28, 2004 - September 1, 2004, Munich, Germany

Authors: Linda Brookes, MSc; Luis Gruberg, MD

This activity is not sanctioned by, nor a part of, the European Society of Cardiology.


Also On This Page:Hot Line SessionsPosters & AbstractsConference News
International Perspectives
Developed in collaboration with our international partners.
Canada Canada
Candesartan in Heart Failure - Assessment of Mortality and Morbidity Trial (CHARM) Low EF
Linda Brookes, MSc
ACTION: A Coronary Disease Trial Investigating Outcome With Nifedipine Gastrointestinal Therapeutic System (GITS) -- A Canadian Thought Leader Perspective From John D. Parker, MD
Linda Brookes, MSc
Hot Line Sessions
INTERHEART: A Global Case-Control Study of Risk Factors for Acute Myocardial Infarction
One of the largest and most important cardiology studies ever conducted, Salim Yusuf's INTERHEART study, has established the baseline for mankind's knowledge of heart disease and should change forever our thinking and our policies for this worldwide cause of death.
A to Z -- Aggrastat to Zocor (TIMI 21) and PRINCESS -- Prevention of Ischemic Events by Early Treatment of Cerivastatin Study
More evidence comes from 2 trials showing that early initiation of statin therapy following an acute coronary syndrome event reduces major cardiovascular events.
Antibiotics in CAD: ACES and PROVE-IT TIMI 22
Do the results of these 2 trials put an end to hopes for the efficacy of antibiotic therapy in patients with atherosclerotic cardiovascular disease?
ACTION: A Coronary Disease Trial Investigating Outcome With Nifedipine Gastrointestinal Therapeutic System (GITS)
Does the use of nifedipine GITS reduce the incidence of MACE compared with placebo? Do the results from ACTION alleviate earlier concerns regarding the drug?
ARTS 1: 5-year Clinical Follow-up of the Arterial Revascularization Therapy Study
Have the clinical results of ARTS comparing PCI with CABG remained consistent out to 5-year follow-up?
DETAIL: Diabetics Exposed to Telmisartan and Enalapril
Are ARBs safe and superior to ACE inhibitors in patients with hypertension and early-stage type 2 diabetic nephropathy?
Dronedarone on Trial: EURIDIS and ADONIS
Two phase 3 trials of dronedarone, a novel class III antiarrhythmic agent, have demonstrated that the drug is safe and effective for the maintenance of sinus rhythm in AF/AFl patients.
E-SIRIUS: 2-Year Clinical Follow-up in Patients With De Novo Lesions Treated With Sirolimus-Eluting Stent
Do the 2-year clinical results of E-SIRIUS show signs of a late catch-up phenomenon?
GAMI: Glucose Abnormalities in Patients With Myocardial Infarction
The GAMI results were not entirely anticipated, and importantly, they point to a potential target for improved secondary preventive efforts against CV morbidity and mortality.
The German Cypher Registry
In Germany, how well do the results of clinical trials evaluating Cypher stent placement match up with real-world clinical practice?
ICTUS: Invasive Versus Conservative Treatment in Unstable Coronary Syndromes
Is an early invasive strategy superior to a selective invasive strategy in patients with non-ST-elevation acute coronary syndrome and elevated troponin T levels?
ISAR-DESIRE: Drug-Eluting Stents for In-Stent Restenosis
Cypher vs Taxus: The drug-eluting stents face off for the prevention of recurrent in-stent restenosis.
JUMBO-TIMI 26: Joint Utilisation of Medications to Block Platelets Optimally
Is prasugrel a viable alternative to clopidogrel in patients undergoing PCI with stents? Will the use of an alternative address the problem of clopidogrel resistance?
PERTINENT: Perindopril, Thrombosis, Inflammation, Endothelial Dysfunction and Neurohormonal Activation Trial
Are there potential vascular and antiatherosclerotic effects of the ACE inhibitor perindopril that might explain the favorable findings from EUROPA?
RIO-Europe: Rimonabant in Obesity - Europe
One-year follow-up results confirm earlier findings reporting the effectiveness of rimonabant to lower body weight and improve metabolic syndrome-associated parameters.
SENIORS: Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors With Heart Failure
Does this study provide more or less support for the use of beta-blockers in the elderly with heart failure?
TAXUS VI: Paclitaxel-Eluting Stents for the Treatment of Longer Lesions -- Focus on Diabetes
Meta-analysis of TAXUS trials demonstrates efficacy of paclitaxel-eluting stent for the treatment of coronary artery disease in diabetic patients.
Posters & Abstracts
Trials in Heart Failure
CHARM Low LVEF: Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Low Left Ventricular Ejection Fraction Trials
Does the addition of the ARB candesartan to standard treatment reduce the rate of deaths and hospitalizations for CHF in CHARM patients with chronic heart failure and low LVEF?
Oral Therapies for the Prevention and Management of Restenosis
IMPRESS-2: Immunosuppressive Oral Prednisone After Percutaneous Interventions in Patients With Multivessel Coronary Artery Disease
How effective is oral prednisone for the prevention of restenosis after PCI in patients with multivessel disease?
OSIRIS: Oral Sirolimus to Inhibit Recurrent In-stent Restenosis Trial
Could oral sirolimus be the magic bullet for patients with in-stent restenosis?
Oral Rapamycin to Prevent Restenosis in Bare Stents: A Single-Blinded, Prospective, Randomized Clinical Trial
Could systematic administration of rapamycin in patients following bare-metal stent implantation be a suitable alternative to drug-eluting stents for the prevention of in-stent restenosis?
ORAR: Oral Rapamycin in Prevention of Angiographic Restenosis
The results of a phase 1 and phase 2 study may assist us in understanding optimal dosing for oral rapamycin for the prevention of restenosis in patients with de novo coronary lesions.
Acute Myocardial Infarction
Randomized Comparison of Prehospital Combination Fibrinolysis vs Prehospital Initiated Facilitated PCI in AMI: Final Results
Should we be aggressive and start treating AMI patients who undergo primary PCI with a "combo" of aspirin, clopidogrel, heparin, thrombolytics, and GP IIb/IIIa inhibitors? Or is it best to wait for more data?
Percutaneous Coronary Intervention vs Fibrinolysis in Acute Myocardial Infarction: the Importance of Timing
What is the relationship between PCI-related time delay and the effectiveness of the intervention in reducing death compared with lytic therapy in acute MI patients?
AMI in The Elderly: The Impact of an Invasive Approach
What is the independent prognostic significance of coronary angiography on mortality in elderly patients with acute myocardial infarction?
Drug-eluting Stents: Chronic Total Occlusions
Paclitaxel Eluting Stents for Treatment of Complex Lesion Subsets: Results of a TAXUS CTO Registry
Should a paclitaxel-eluting stent be the standard of care for patients with chronic total occlusions?
Treatment of Chronic Total Occlusion With the Sirolimus-Eluting Stent: Initial Results From the e-CYPHER Registry
What about the use of sirolimus-eluting stents for the treatment of CTOs?
Conference News
"Polypill": Pros and Cons
[Medscape Cardiology]
How viable is a polypill approach for patients at high risk for CVD? What are the implications for risk factor management, patient compliance, and outcomes?
TAXUS and Cypher Show Benefit Over Balloon Angioplasty 9/2/04
[Medscape Medical News]
But results of the head-to-head study suggest that of the two drug-eluting stents, Cypher may be more effective than TAXUS.
No Mortality Difference Between CABG and Stents at 5 Years 9/2/04
[Medscape Medical News]
Coronary artery bypass graft surgery was also associated with a significantly lower revascularization rate.
Perindopril Survival Benefit May Be Enhanced by Effect on Endothelium 9/2/04
[Medscape Medical News]
The drug slows the apoptosis rate in endothelial cells, according to results of the PERTINENT trial.
Early, Aggressive Treatment With High-Dose Simvastatin Fails to Achieve Benefit 8/31/04
[Medscape Medical News]
Poor safety profile casts doubt on high-dose regimen, according to a randomized study.
Both ACE Inhibitors and ARBs Slow Renal Decline in Type 2 Diabetes 8/31/04
[Medscape Medical News]
The mortality rate was also decreased with either agent in this head-to-head comparison.
Rimonabant May Reduce Both Weight and Waist Circumference 8/30/04
[Medscape Medical News]
Phase III results confirm early positive reports.
CVD Risk Factors Equally Dangerous Regardless of Race, Ethnicity 8/30/04
[Medscape Medical News]
Hyperlipidemia and smoking account for 66% of heart disease, according to the study.

 
Legal Disclaimer
The materials presented here were prepared by independent authors under the editorial supervision of Medscape, and do not represent a publication of the European Society of Cardiology. These materials and the related activity are not sanctioned by the European Society of Cardiology or the commercial supporter of the conference, and do not constitute an official part of that conference.
The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2004 Medscape.

 
WebMD
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.